AVIR - Aviragen Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue8,9009,30024,600
Cost of Revenue--3,600
Gross Profit8,9009,30021,000
Operating Expenses
Research Development28,30026,30019,800
Selling General and Administrative8,0008,0009,400
Non Recurring--17,600
Total Operating Expenses---
Operating Income or Loss-27,500-25,200-19,500
Income from Continuing Operations
Total Other Income/Expenses Net100-1006,600
Earnings Before Interest and Taxes-27,300-25,100-19,200
Interest Expense1,800300300
Income Before Tax-29,100-25,400-19,200
Income Tax Expense300--100
Minority Interest---
Net Income From Continuing Ops-29,400-25,400-19,100
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-29,400-25,400-19,100
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-29,400-25,400-19,100